Next 10 |
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what curre...
2024-06-27 12:14:11 ET More on Myriad Genetics Myriad Genetics collaborates with GSK for HRD testing in 9 countries Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript Seeking A...
2024-06-26 17:30:02 ET Scotiabank analyst issues OUTPERFORM recommendation for MYGN on June 26, 2024 04:14PM ET. MYGN was trading at $24.62 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 2 - Buy, 5 - Ho...
2024-06-26 17:00:11 ET Sung Ji Nam from Scotiabank issued a price target of $29.00 for MYGN on 2024-06-26 16:14:00. The adjusted price target was set to $29.00. At the time of the announcement, MYGN was trading at $24.62. The overall price target consensus is at $24.33 w...
SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight ® Mental Health Monitor: Special Election Series, a nationwide survey from Myria...
2024-06-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-11 08:38:35 ET More on Myriad Genetics Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript Myriad Genetics surges 17% as Street applauds 2024 guidance, Q1 results Myriad Genetics GAAP EPS of -$0.29 beats by $0.01, revenue of $202.2M beats by $8.95M ...
SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ...
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight ® Carrier Screen . The panel includes 39 conditions and screens ...
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine , an official journal of the American College of Medical Genetics and Genomics (ACMG), published a ...
News, Short Squeeze, Breakout and More Instantly...
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what curre...
2024-06-26 17:30:02 ET Scotiabank analyst issues OUTPERFORM recommendation for MYGN on June 26, 2024 04:14PM ET. MYGN was trading at $24.62 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 2 - Buy, 5 - Ho...
2024-06-26 17:00:11 ET Sung Ji Nam from Scotiabank issued a price target of $29.00 for MYGN on 2024-06-26 16:14:00. The adjusted price target was set to $29.00. At the time of the announcement, MYGN was trading at $24.62. The overall price target consensus is at $24.33 w...